Menu

Filtros : "Current Pharmaceutical Design" "ICB" Limpar

Filtros

Refine with date range

  • 1

1 - 6 (6 records)

  • Artigo de periodico

    Feeding pattern, circadian rhythm, and immune function: what do we know about? (2022)

    Estanislau, Thiago Barros ; Krüger, Karsten; Rosa Neto, José Cesar ; Padilha, Camila S. ; Gonçalves, Daniela Caetano ; Minuzzi, Luciele Guerra ; Lira, Fabio Santos

    Source: Current Pharmaceutical Design. Unidade: ICB

    Subjects: BIOLOGIA CELULAR, NUTRIÇÃO, OBESIDADE, ALIMENTAÇÃO, RITMOS BIOLÓGICOS, RITMO CIRCADIANO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      ESTANISLAU, Thiago Barros et al. Feeding pattern, circadian rhythm, and immune function: what do we know about?. Current Pharmaceutical Design, v. 28, n. 30, p. 2478-2487, 2022Tradução . . Disponível em: https://doi.org/10.2174/1381612828666220729091451. Acesso em: 16 nov. 2025.

    • APA

      Estanislau, T. B., Krüger, K., Rosa Neto, J. C., Padilha, C. S., Gonçalves, D. C., Minuzzi, L. G., & Lira, F. S. (2022). Feeding pattern, circadian rhythm, and immune function: what do we know about? Current Pharmaceutical Design, 28( 30), 2478-2487. doi:10.2174/1381612828666220729091451

    • NLM

      Estanislau TB, Krüger K, Rosa Neto JC, Padilha CS, Gonçalves DC, Minuzzi LG, Lira FS. Feeding pattern, circadian rhythm, and immune function: what do we know about? [Internet]. Current Pharmaceutical Design. 2022 ; 28( 30): 2478-2487.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/1381612828666220729091451

    • Vancouver

      Estanislau TB, Krüger K, Rosa Neto JC, Padilha CS, Gonçalves DC, Minuzzi LG, Lira FS. Feeding pattern, circadian rhythm, and immune function: what do we know about? [Internet]. Current Pharmaceutical Design. 2022 ; 28( 30): 2478-2487.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/1381612828666220729091451

  • Artigo de periodico-carta/editorial

    Immunometabolism disorders: pharmacologic and nonpharmacologic approaches (2020)

    Lira, F. S.; Rosa Neto, José Cesar

    Source: Current Pharmaceutical Design. Unidade: ICB

    Subjects: BIOLOGIA CELULAR, METABOLISMO, DOENÇAS METABÓLICAS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      LIRA, F. S. e ROSA NETO, José Cesar. Immunometabolism disorders: pharmacologic and nonpharmacologic approaches. Current Pharmaceutical Design. Sharjah: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.2174/138161282609200423142125. Acesso em: 16 nov. 2025. , 2020

    • APA

      Lira, F. S., & Rosa Neto, J. C. (2020). Immunometabolism disorders: pharmacologic and nonpharmacologic approaches. Current Pharmaceutical Design. Sharjah: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.2174/138161282609200423142125

    • NLM

      Lira FS, Rosa Neto JC. Immunometabolism disorders: pharmacologic and nonpharmacologic approaches [Internet]. Current Pharmaceutical Design. 2020 ; 26( 9): 905.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/138161282609200423142125

    • Vancouver

      Lira FS, Rosa Neto JC. Immunometabolism disorders: pharmacologic and nonpharmacologic approaches [Internet]. Current Pharmaceutical Design. 2020 ; 26( 9): 905.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/138161282609200423142125

  • Artigo de periodico

    Nitric oxide donors as ootential drugs for the treatment of vascular diseases due to endothelium dysfunction (2020)

    Paulo, Michele ; Costa, Daniela E. F. R.; Bonaventura, Daniella; Lunardi, Claure N.; Bendhack, Lusiane Maria

    Source: Current Pharmaceutical Design. Unidades: FCFRP, ICB

    Subjects: CÉLULAS ENDOTELIAIS, ENDOTÉLIO VASCULAR, ÓXIDO NÍTRICO, FARMACOLOGIA, DOENÇAS VASCULARES

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      PAULO, Michele et al. Nitric oxide donors as ootential drugs for the treatment of vascular diseases due to endothelium dysfunction. Current Pharmaceutical Design, v. 26, n. 30, p. 3748-3759, 2020Tradução . . Disponível em: https://doi.org/10.2174/1381612826666200519114442. Acesso em: 16 nov. 2025.

    • APA

      Paulo, M., Costa, D. E. F. R., Bonaventura, D., Lunardi, C. N., & Bendhack, L. M. (2020). Nitric oxide donors as ootential drugs for the treatment of vascular diseases due to endothelium dysfunction. Current Pharmaceutical Design, 26( 30), 3748-3759. doi:10.2174/1381612826666200519114442

    • NLM

      Paulo M, Costa DEFR, Bonaventura D, Lunardi CN, Bendhack LM. Nitric oxide donors as ootential drugs for the treatment of vascular diseases due to endothelium dysfunction [Internet]. Current Pharmaceutical Design. 2020 ; 26( 30): 3748-3759.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/1381612826666200519114442

    • Vancouver

      Paulo M, Costa DEFR, Bonaventura D, Lunardi CN, Bendhack LM. Nitric oxide donors as ootential drugs for the treatment of vascular diseases due to endothelium dysfunction [Internet]. Current Pharmaceutical Design. 2020 ; 26( 30): 3748-3759.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/1381612826666200519114442

  • Artigo de periodico

    Protein disulfide isomerase and Nox: new partners in redox signaling (2015)

    Trevelin, Silvia Cellone; Lopes, Lucia Rossetti

    Source: Current Pharmaceutical Design. Unidade: ICB

    Assunto: FARMACOLOGIA

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      TREVELIN, Silvia Cellone e LOPES, Lucia Rossetti. Protein disulfide isomerase and Nox: new partners in redox signaling. Current Pharmaceutical Design, v. 21, n. 41, p. 5951-5963, 2015Tradução . . Disponível em: https://doi.org/10.2174/1381612821666151029112523. Acesso em: 16 nov. 2025.

    • APA

      Trevelin, S. C., & Lopes, L. R. (2015). Protein disulfide isomerase and Nox: new partners in redox signaling. Current Pharmaceutical Design, 21( 41), 5951-5963. doi:10.2174/1381612821666151029112523

    • NLM

      Trevelin SC, Lopes LR. Protein disulfide isomerase and Nox: new partners in redox signaling [Internet]. Current Pharmaceutical Design. 2015 ; 21( 41): 5951-5963.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/1381612821666151029112523

    • Vancouver

      Trevelin SC, Lopes LR. Protein disulfide isomerase and Nox: new partners in redox signaling [Internet]. Current Pharmaceutical Design. 2015 ; 21( 41): 5951-5963.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/1381612821666151029112523

  • Artigo de periodico

    Potential of peptide-based enhancers for transdermal delivery (2015)

    Lopes, Luciana Biagini ; Carvalho, Vanessa Freitas Mendonça de; Lemos, Débora P. de

    Source: Current Pharmaceutical Design. Unidade: ICB

    Subjects: FARMACOLOGIA, PEPTIDEOS

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      LOPES, Luciana Biagini e CARVALHO, Vanessa Freitas Mendonça de e LEMOS, Débora P. de. Potential of peptide-based enhancers for transdermal delivery. Current Pharmaceutical Design, v. 21, n. 20, p. 2814-2822, 2015Tradução . . Disponível em: https://doi.org/10.2174/1381612821666150428143243. Acesso em: 16 nov. 2025.

    • APA

      Lopes, L. B., Carvalho, V. F. M. de, & Lemos, D. P. de. (2015). Potential of peptide-based enhancers for transdermal delivery. Current Pharmaceutical Design, 21( 20), 2814-2822. doi:10.2174/1381612821666150428143243

    • NLM

      Lopes LB, Carvalho VFM de, Lemos DP de. Potential of peptide-based enhancers for transdermal delivery [Internet]. Current Pharmaceutical Design. 2015 ; 21( 20): 2814-2822.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/1381612821666150428143243

    • Vancouver

      Lopes LB, Carvalho VFM de, Lemos DP de. Potential of peptide-based enhancers for transdermal delivery [Internet]. Current Pharmaceutical Design. 2015 ; 21( 20): 2814-2822.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/1381612821666150428143243

  • Artigo de periodico

    The uniqueness of the Trypanosoma cruzi mitochondrion: opportunities to target new drugs against chagas´ disease (2011)

    Paes, Lisvane Silva; Mantilla, Brian Suárez; Barisón, Maria Julia; Wrenger, Carsten ; Silber, Ariel Mariano

    Source: Current Pharmaceutical Design. Unidade: ICB

    Assunto: PARASITOLOGIA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      PAES, Lisvane Silva et al. The uniqueness of the Trypanosoma cruzi mitochondrion: opportunities to target new drugs against chagas´ disease. Current Pharmaceutical Design, v. 17, n. 20, p. 2074-2099, 2011Tradução . . Disponível em: https://doi.org/10.2174/138161211796904786. Acesso em: 16 nov. 2025.

    • APA

      Paes, L. S., Mantilla, B. S., Barisón, M. J., Wrenger, C., & Silber, A. M. (2011). The uniqueness of the Trypanosoma cruzi mitochondrion: opportunities to target new drugs against chagas´ disease. Current Pharmaceutical Design, 17( 20), 2074-2099. doi:10.2174/138161211796904786

    • NLM

      Paes LS, Mantilla BS, Barisón MJ, Wrenger C, Silber AM. The uniqueness of the Trypanosoma cruzi mitochondrion: opportunities to target new drugs against chagas´ disease [Internet]. Current Pharmaceutical Design. 2011 ; 17( 20): 2074-2099.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/138161211796904786

    • Vancouver

      Paes LS, Mantilla BS, Barisón MJ, Wrenger C, Silber AM. The uniqueness of the Trypanosoma cruzi mitochondrion: opportunities to target new drugs against chagas´ disease [Internet]. Current Pharmaceutical Design. 2011 ; 17( 20): 2074-2099.[citado 2025 nov. 16 ] Available from: https://doi.org/10.2174/138161211796904786
  • 1

1 - 6 (6 records)

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2025